This round is a bet that continuous biochemical monitoring is moving from lab promise to clinical workflow.
Swiss wearable biosensing company Xsensio has raised EUR 6.65 million (reported as $7 million) in an oversubscribed Series A led by WI Harper, with participation from Privilège Ventures, the European Innovation Council (EIC) and private investors, according to FinSMEs. The company said it will use the proceeds to accelerate development and clinical validation of its Lab-on-Skin wearable biosensing platform.
The financing lands as European investors continue to back continuous and wearable monitoring. Recent disclosed activity includes more than EUR 42 million invested into European startups in continuous and wearable health monitoring across 2025 to early 2026, including rounds for Sava Technologies (EUR 16.6 million) and Liom (EUR 13.9 million).
Why this round matters
Xsensio sits in a segment that has historically struggled to cross the gap between engineering feasibility and clinical adoption. Management is explicitly positioning this raise as a step into real-world healthcare settings. CEO Esmeralda Megally described the Series A as a pivotal step in translating continuous biochemical monitoring into real clinical environments.
From the investor side, WI Harper said Xsensio is defining a new category in wearable biosensing, pointing to progress to date and market potential. The company has also been recognized by TIME as one of the World’s Top HealthTech Companies of 2025, a useful credibility marker in a field where validation and trust often determine commercial timelines.
Execution focus: clinical validation and manufacturability
Xsensio’s stated use of proceeds is clear: build and validate, not just iterate prototypes. For wearable biochemical sensing, the proof points that typically unlock broader deployment are clinical validation, repeatability at scale, and integration into existing care pathways.
A notable industrial element is Xsensio’s long-term collaboration with Texas Instruments, focused on CMOS integration, miniaturization and large-scale manufacturing. That partnership speaks to a common bottleneck in biosensing: even if a sensor works in controlled conditions, scaling it into a manufacturable, cost-effective product with consistent performance is a different challenge.
Market read-through
The deal fits a broader direction of travel in health monitoring: the shift from intermittent measurements to real-time, continuous biochemical data. Investors have increasingly been willing to fund platforms that can plausibly support that shift, particularly when companies can demonstrate a path to clinical evidence and scalable production.
Xsensio’s board leadership has framed the company as uniquely positioned to help drive the transformation toward personalized and preventive healthcare through continuous monitoring. Whether the platform can deliver on that ambition will depend on execution in the next stage: clinical validation milestones, regulatory strategy, and the ability to translate sensor output into actionable insights for clinicians and patients.
Risks to watch
The core risk is not novelty but adoption: clinical validation and integration into healthcare settings can extend timelines and raise costs. Manufacturing scale-up is another pressure point, even with a major semiconductor partner, because biosensing performance and yield consistency can degrade when moving from small batches to volume production.
For now, the oversubscribed Series A and the mix of venture and institutional participation indicate investors see momentum in Xsensio’s approach and in the broader continuous monitoring category.